PitchSend

Investor Presentaiton

Investor presentation Full year 2018 Slide 56 Novo Nordisk increases its market share in the long-acting insulin segment USA fast-acting insulin Segment volume USA premix insulin Segment volume USA long-acting insulin Segment volume LevemirⓇ share FIASPⓇ share NovoLogⓇ share Combined NN tMU CAGR volume¹: 2.8% tMU 80 MI penetration: 83.7% 80% 80 - NovoLog® Mix 70/30 share CAGR volume¹: (6.2%) MI penetration: 51.3% TresibaⓇ share Combined NN tMU CAGR volume¹: 3.4% 80% 80 MI penetration²: 72.0% 80% 60 60 60% 60 60% 60 60 60% 40 20 20 40% 40 - 20% 20 0 0% 0 Nov 2013 Nov 2018 Nov 2013 1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units 40% 40- - 20% 20- 0% 0 Nov 2018 Nov 2013 Note: The USA trend data reflect changes to IQVIA data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, i.e. including human insulin Source: IQVIA monthly MAT Nov, 2018 volume figures NN: Novo Nordisk changing diabetes 40% + 20% 0% Nov 2018 novo nordisk

View entire presentation